Nitric oxide vs Sildenafil for pulmonary artery reactivity testing in heart transplantation candidates

Magdalena Nowacka, Grzegorz Kopeć, Jakub Stępniewski, Piotr Podolec

Full Text:

PDF

Abstract


In idiopathic pulmonary arterial hypertension (IPAH) nitric oxide (NO) is an agent of choice for pulmonary artery (PA) reactivity testing. Contrary, currently there is no standardized protocol for PA reactivity testing in patients with pulmonary hypertension (PH) associated with left heart disease and several vasodilator agents are suggested for this procedure. We aimed to assess whether standard protocol of PA reactivity testing used in IPAH is useful in patients with severe PH due to severe systolic dysfunction of a left ventricle. During right heart catheterization we assessed hemodynamic parameters in 14 patients at baseline, during NO inhalation and 30 minutes after oral administration of sildenafi l. We observed a significant decrease in PA pressure and resistance, and increase in cardiac index after sildenafil but not after NO administration. We conclude that standard protocol for PA reactivity in IPAH is not useful in patients with PH due to severe left ventricular systolic dysfunction. JRCD 2012; 1: 7–9


Keywords


Pulmonary hypertension due to left heart disease; Qualification for heart transplant

References


Nazzareno G, Marius MH, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493–2537.

Stobierska-Dzierzek B, Awad H, Michler RE. The evolving management of acute right - sided heart failure in cardiac transplant recipients. J Am Coll Cardiol 2001; 38: 923–931.

Mehra MR, Kobashigawa J, Starling R, et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006, J Heart Lung Transplant 2006; 25: 1024–1042.

Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J2008; 29: 270–276.

Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiography 2006; 7: 79–108.

Lepore JJ Maroo A, Bigatello LM et al. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: com bined administration with inhaled nitric oxide. Chest 2005; 127: 1647–1653.

Loh E, Stamler JS, Hare JM, et al. Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994; 90




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol1no1.22

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl